RIUNIONE’NAZIONALE’FIL FONDAZIONEI TALIANAL INFOMI !! … · 2020. 9. 18. · ,4!,6!,8! 1! Time...
Transcript of RIUNIONE’NAZIONALE’FIL FONDAZIONEI TALIANAL INFOMI !! … · 2020. 9. 18. · ,4!,6!,8! 1! Time...
RIUNIONE NAZIONALE FIL FONDAZIONE ITALIANA LINFOMI
R-‐BAC500
Carlo Visco Ospedale San Bortolo, Vicenza
Rimini 3 O5obre 2014
DISCLOSURES
Relatore: Carlo Visco
• Fondi per la ricerca: MUNDIPHARMA PHARMACEUTICALS
• Partecipazione ad Advisory Board: CELGENE, MUNDIPHARMA
INTERNATIONAL, LUNDBECK CANADA
Treatment scheme (R-‐BAC)
1 2 3 4 Rituximab 375 mg/m2 BendamusBne 70 mg/m2 Ara-‐C 800 mg/m2
G-‐CSF 5 µg/kg
Upfront Relapsed/Refractory
-‐Elderly MCL-‐ ProvocaBve comparison
Time (months) 0 ,2 ,4 ,6 ,8 1
Time (months) R-Lena, Ibrutinib, R-FCM 12-14 months
R-Benda 16-20 months
PFS
R-BAC R-BAC 37 months
R-Benda 35 months
R-CHOP 16-24 months
0 10 20 30 40 50 0 10 20 30 40 50 0 ,2 ,4 ,6 ,8 1
R-‐BAC500 FIL
• Ara-‐C dose reducBon to 500 mg/m2 • IntroducBon of MRD and CGA assessment • Two stage, phase 2 study (Bryant and Day two-‐stage design) • Previously untreated >65 years or 60-‐65 unfit • Primary objecBves: CR rate (Cheson criteria 2007) and safety
Enrollment curve
0
10
20
30
40
50
60
70
80
40969
41030
41091
41153
41214
41275
41334
41395
41456
41518
41579
41640
Pazi
enti
Mesi
Attivazione Centri
Arruolamento Pazienti
Arruolamento ideale se tutti centri sono attivi a partire dal momento 0
Arruolamento ideale se è dato il numero di centri attivi
Enrollment suspended for 6 months [«interim analysis»] to finalize treatment of 19
paMents
1st pt 2 May 2012
57th pt 25 Feb 2014
Protocol Flow Chart Baseline PET+MRD
Intermediate MRD (before cycle 3)
Final PET+MRD (End of treatment)
Study Flow
57 patients enrolled 303 delivered cycles
57 patients had at least 2 cycles
53 patients had at least 4 cycles
36 patients had 6 cycles
4 paMents diconBnued due to toxicity/AE
11 paMents diconBnued due to toxicity/AE; 1 PD; 5 doctor/paMent decision;
1) Novara 5 2) Vicenza 4 3) Palermo«Cervello» 4 4) Torino Em2 3 5) Aviano 3 6) Rimini 3 7) Ravenna 3 8) Firenze 3 9) Torino Em1 2 10) Varese 2 11) Roma «Sapienza» 2 12) Siena 2 13) Padova 2 14) Pavia 2 15) Genova «San M» 2 16) Alessandria 2 Monza, Terni, Bolzano, Brescia, Cagliari, Mirano, Milano N, Milano OM, Piacenza, Reggio C, Reggio E, Udine, Verona 1
Overall (57) % Age, years median range
71
61-‐79
Gender male female
43 14
75 25
Performance Status 0-‐1 >1
51 6
89 11
Histology Classic MCL Blastoid variant
52 5
91 9
AAS I-‐II III-‐IV
5 52
9 91
MIPI risk category low risk intermediate risk high risk
9 29 19
16 51 33
BM involvement 36 63
Elevated LDH 20 35
PaBents Demographics and Disease CharacterisBcs at Baseline
Hematological Toxicity Delivered cycles: 303
Overall
Grade 0 1 2 3 4
Leukopenia -‐ 30% 26% 17% 27%
Neutropenia -‐ 15% 36% 14% 35%
Febrile neutropenia 94% 5% 1%
Thrombocytopenia -‐ 14% 34% 16% 36%
Anemia 21% 24% 43% 12% <1%
Platelet transfusion 89 of 303 (29%) Platelet transfusion per patient: 28 of 57 (49%). Febrile neutropenia: median duration 3.4 days (1-10) Data refer to cycles with at least 1 day of event. PaBents were monitored every other day between day +8 and +12, or unBl resoluBon of cytopenia aier the end of cycles.
17%
28%
4%
12%
64%
R-‐BAC JCO 2013
Grade 4
62%
All grades Grade 3 Grade 4
Event N paBents % N paBents % N paBents %
Nausea/vomiBng 12 21 0 0 0 0 StomaBBs 3 5 0 0 0 0 ConsBpaBon/Dhyarrea 6 10 0 0 0 0
Infusion related/TLS 12 21 1 2 0 0
FaBgue 14 25 1 2 NA NA Documented infecBons 5 9 5* 9 2** 4 g-‐GT/GOT-‐GPT elevaBon 7 12 1 2 0 0 Alopecia 3 5 0 0 0 0 Rash/desquamaBon 5 9 0 0 0 0 Cardiac 3 5 2^ 3 1*** 2
Non-‐hematological Toxicity occurring in more than 1 paTent
*HZV reacBvaBon, infecBon of the surgical wound, CMV reacBvaBon (2), fungal infecBon; **Pseudomonas Aeruginosa and Gram+ sepsis; ***Myocardial infarcBon with cerebral ischemia; ^Atrial fibrillaBon, chest pain.
Disease response
A]er 2 cycles
%
End of treatment*
%
N=57 N=54
ORR CR PR SD PD
57 21 36 -‐ -‐
100 37 63 -‐ -‐
52 50 2** -‐ 2
96 92 4 -‐ 4
92% PET-‐negaBve CR * 36 (63%) patients after 6 cycles; 6 (10%) after 5; 11 (19%) after 4; 4 (7%) after <4. ** Had 2 and 3 cycles respectively (withdrawn for toxicity)
0.00
0.25
0.50
0.75
1.00
57 52 22 14 1 At risk:
0 6 12 18 24Months from Enrollment
Median follow-up 11 months (3-24)
0.00
0.25
0.50
0.75
1.00
57 53 23 15 1 At risk:
0 6 12 18 24Months from Enrollment
PFS OS
Survival curves
Conclusioni-‐Riflessioni
• R-BAC500 si associa ad un alto tasso di risposte complete (92%), simile a R-BAC800
• Quasi tutti i pazienti sono in grado di ricevere almeno 4 cicli
• La tossicità ematologica rimane importante • Nonostante l’alto tasso di neutropenie transitorie gli
episodi infettivi sono comparabili a r-benda o r-chop • La tossicità non ematologica di grado 3-4 si conferma
più che accettabile • Il follow-up è ancora breve per considerazioni sul PFS